Kamada has submitted a BLA to the FDA for its lead clinical candidate, intravenous alpha-1 antitrypsin, for the treatment of AAT. <a href="http://www.globes.co.il/serveen/globes/docview.asp?did=1000454873&fid=942" rel="nofollow" target="_blank">http://www.globes.co.il/serveen/globes/docview.asp?did=1000454873&fid=942</a>